18
Sep

Fresh from writing off one of its top late-stage programs, Merck KGaA stepped up with a revised comeback plan today, detailing plans to invest about $500 million in a late-stage effort to develop new biosimilars while scouting for a major-league partner to come in on its PD-L1 immuno-oncology program. And the company pointed to its current lineup of three star players in the pipeline, including one that has already posted a clinical failure.

…read more

Source: Struggling Merck KGaA plans blockbuster R&D campaign for biosimilars, pact for PD-L1

    

0 No comments